posted on 2020-09-07, 07:43authored byAlexandra Bukchin, Macarena Sanchez-Navarro, Adam Carrera, Meritxell Teixidó, Angel M. Carcaboso, Ernest Giralt, Alejandro Sosnik
The blood–brain
barrier (BBB) is a challenge for the treatment
of diseases of the central nervous system (CNS) from the systemic
circulation. The design of novel strategies to increase drug bioavailability
in the CNS is called for. In this work, we synthesized amphiphilic
polymeric nanoparticles by the self-assembly of graft copolymers of
chitosan (CS, hydrophilic copolymer backbone) hydrophobized in the
side-chain with poly(methyl methacrylate) (PMMA)/poly(acrylic acid)
(PAAc) blocks and surface-decorated with a biologically stable retro-enantio
peptide shuttle that improves brain transport. Nanoparticles showed
one size population in the 190–210 nm range (intensity distribution)
and a relatively small polydispersity index, as measured by dynamic
light scattering. The surface charge estimated by the zeta-potential
decreased from +35 mV in the unmodified nanoparticles to +14 mV in
the modified ones, confirming the exposure of the peptide shuttle
at the nanoparticle surface. The cell compatibility and uptake were
assayed in hCMEC/D3 cells, a model of BBB endothelium, by a metabolic
assay, confocal laser scanning fluorescence microscopy, and imaging
flow cytometry in the absence and the presence of endocytosis inhibitors.
Results indicated that the peptide shuttle modification improves their
cell compatibility and that they are internalized by a clathrin-mediated
pathway. In vitro permeability studies conducted
in hCMEC/D3 cell monolayers showed that peptide shuttle-modified nanoparticles
increase the apparent permeability with respect to the unmodified
ones by 3.4 times. Finally, the brain accumulation was investigated
upon i.v. administration to Hsd:ICR mice by using fluorescently labeled
nanoparticles in an in vivo imaging system and light
sheet fluorescence microscopy. Unmodified nanoparticles could be hardly
detected in the brain blood vessels and parenchyma. Conversely, nanoparticles
modified with the peptide shuttle could be detected after 10 min,
with a maximum accumulation at 30 min and a slow concentration decline
later on. Calculation of the area under the curve confirmed a 4-fold
statistically significant increase in the accumulation of the modified
nanoparticles with respect to the unmodified counterparts. These findings
demonstrate the promise of this strategy to improve the delivery of
nanoencapsulated cargos to the CNS.